OPINION: drug firms say no to rebates, despite billions in new revenue from Part D

By Wendell Potter

Part D brought drug companies billions, but they say the sky is falling

Drug lobby donation went to pro-Democratic nonprofit

By Michael Beckel

Half-million-dollar donation from PhRMA went to little-known group that backed Harry Reid.

Federal regulators have failed to act on toxic chemical, report says

By Chris Hamby

Regulators have done little to protect the public from BPA, critics say

Report faults Medicare controls on widely abused drugs

By Joe Eaton

Beneficiaries easily went to multiple doctors for hydrocodone and oxycodone

Inspectors struggle to keep up with flood of imports

By Brad Racino

Food imports approved for use in the U.S. in an unexpected way

Investigations Around the World

By Simona Raetz

Drug on wars makes pain killers unavailable for patients in developing countries; mining companies are big winners of Chilean tax system

FDA's flimsy recall power for food imports puts public at risk, watchdog says

By Aaron Mehta and Ben Wieder

FDA needs more power to police recalls of imported foods

FDA screening of fish imports not catching antibiotics and drug residue

By Laurel Adams

FDA taken to task for sloppy inspections of imported fish

During Mitch Daniels’ decade at Eli Lilly, the drug giant paid billions in fines and settled thousands of lawsuits

By Joanne Kenen and Rochelle Sharpe

Eli Lilly paid billions in fines, settled thousands of lawsuits while Daniels was an executive at the drug giant

Medicare can’t identify top prescribers of addictive drugs

By The Center for Public Integrity and Joe Eaton

Medicare doesn't know if all the prescriptions it is paying for are being written by real doctors, says a new inspector general's report....

FDA criticized for accepting free help from company that later won generic OK

By Laurel Adams

The Food and Drug Administration last month issued guidelines for agency staff to follow when drugmakers offer free help during emergencies

In health, like everything else, men and women really are different

By Amy Biegelsen

Health studies still do not adequately root out differences between men and women, according to a new report from the National Academy of Sc

Most drug trial results analyzed by FDA hidden from view

By Naseem Miller

Before a new drug finds its place on pharmacy shelves or a new device lands in the hands of a surgeon, it goes through a long and complex ap

FDA lags USDA in accessible food safety data

By Jim Morris

Recent outbreaks of food-borne illness left American consumers on edge — and largely in the dark about federal enforcement. The Food and Dru

FDA reaches agreement with firm that produced troubled heart drug

The U.S. Food and Drug Administration last week announced a little-noticed tentative agreement setting conditions under which a troubled pha

Did the FDA miss signals on a troubled heart drug?

By Jeanne Lenzer

It has been a rough eight months for the drug maker Actavis, Inc. and its powerful heart drug, Digitek. Following repeated Food and Drug Adm

FDA enforcement actions way down

By The Center for Public Integrity

Enforcement actions by the (FDA) markedly declined under the Bush administration

Lack of adequate foreign drug oversight

By The Center for Public Integrity

The GAO called for improvement in the FDA’s Foreign Drug Inspection Program in 1998. A decade later, there's been little improvement.

FDA failure to ensure drug safety

By The Center for Public Integrity

Vioxx dangers raise questions about FDA's ability to monitor drugs

More big money from pharmaceutical lobby in 2008

By Mary Beth Lombardo

The economy may be sliding, but that hasn’t stemmed the high-rolling habits of Washington’s largest lobby. In 2007, as the Center recently r

A record year for the pharmaceutical lobby in '07

By M. Asif Ismail

Washington's largest lobby racks up another banner year on Capitol Hill

Spending on lobbying thrives

By M. Asif Ismail

Drug and health products industries invest $182 million to influence legislation

PEPFAR policy hinders treatment in generic terms

By M. Asif Ismail

Critics say FDA approval rule has meant greater use of high-cost drugs at expense of helping fewer patients

Drug makers' dime funds Congressional travel

By Robert Brodsky

Pharmaceutical companies, affiliated trade groups spent more than $600,000 on trips

Deep pockets contribute to success

By M. Asif Ismail

Industry spends millions on state campaign donations, Calif. fight

States see importation as solution to high drug costs

By Victoria Kreha

Several seek, have plans despite federal and industry opposition

FDA staff travels on drug industry dollars

By Alexander Cohen

Groups tied to FDA-regulated industry paying for agency officials' trips

Checkbook politics

By Victoria Kreha

Over the last seven years, the pharmaceutical industry has given $150 million in campaign contributions

Drug industry influence timeline

What the pharmaceutical industry has gotten on its political investment

Drug lobby second to none

By M. Asif Ismail

How the pharmaceutical industry gets its way in Washington

Pages